Preview

Eurasian heart journal

Advanced search

Heart failure in Duchenne's progressive muscular dystrophy (case report)

https://doi.org/10.38109/2225-1685-2026-1-64-69

Abstract

Progressive Duchenne muscular dystrophy is a common X-linked recessive myopathy caused by a mutations in the gene encoding dystrophin. Duchenne muscular dystrophy is characterized by damage to the heart muscle with conduction and rhythm disturbances, and the development of dilated cardiomyopathy, which may be asymptomatic. The development of heart failure determines the unfavorable prognosis of patients with Duchenne muscular dystrophy. Insufficient awareness of physicians about the characteristics of heart damage in Duchenne muscular dystrophy creates the prerequisites for describing interesting clinical observations. The article presents a clinical observation of the development of dilated cardiomyopathy and heart failure with a low left ventricular ejection fraction in a 19-year-old male patient with Duchenne muscular dystrophy. The dynamics of Duchenne muscular dystrophy progression from the moment of diagnosis to the development of decompensated heart failure are described. The article presents clinical course data, laboratory parameters, electrocardiography and echocardiography data in dynamics. The article presents diagnostic criteria for Duchenne muscular dystrophy, prospects for therapy aimed at correcting the genetic defect by replacing, modifying or reparating the dystrophin gene. The presented case demonstrates the need for a personalized multidisciplinary approach to a patient with Duchenne muscular dystrophy, with the participation of an orthopedic surgeon, pulmonologist, cardiologist, endocrinologist, and ophthalmologist.

About the Authors

S. D. Mayanskaya
Kazan State Medical University
Russian Federation

Svetlana D. Mayanskaya, Dr. of Scien. (Med.), Professor, Department of Hospital Therapy



O. V. Bulashova
Kazan State Medical University
Russian Federation

Olga V. Bulashova, Dr. of Scien. (Med.), Professor, S.S. Zimnitsky Department of Propaedeutics of Internal Diseases



E. I. Mukhitova
M.N. Sadykov City Clinical Hospital no 7
Russian Federation

Elza I. Mukhitova, cardiologist, cardiology department No. 4



E. V. Khazova
Kazan State Medical University
Russian Federation

Elena V. Khazova, Dr. of Scien. (Med.), Associate Professor, S.S. Zimnitsky Department of Propaedeutics of Internal Diseases



References

1. Muscular dystrophy, Duchenne type; DMD (#310200). [accessed: 06.01.2025]. https://www.omim.org/entry/310200

2. Гайнетдинова Д.Д., Новоселова А.А. Современные возможности диагностики и лечения мышечной дистрофии Дюшенна. Казанский мед. ж. 2020;101(4):530–537. https://doi.org/10.17816/KMJ2020-530 [Gaynetdinova D.D., Novoselova A.A. Current diagnosis and treatment of Duchenne muscular dystrophy. Kazan Medical Journal. 2020;101(4):530–537. (In Russ.) https://doi.org/10.17816/KMJ2020-530 ]

3. Meyers T.A., Townsend D. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy. Int J Mol Sci. 2019;20(17):4098. https://doi.org/10.3390/ijms20174098

4. Tang L., Shao S., Wang C. Electrocardiographic features of children with Duchenne muscular dystrophy. Orphanet J Rare Dis. 2022;17(1):320. https://doi.org/10.1186/s13023-022-02473-9

5. Анисимова И.В., Артемьева С.Б., Белоусова Е.Д., и др. Мышечная дистрофия Дюшенна: современные подходы к ведению и лечению пациентов. Педиатрическая фармакология. 2023;20(5):427–453. https://doi.org/10.15690/pf.V20i5.2615 [Anisimova I.V., Artemyeva S.B., Belousova E.D. et al. Duchenne Muscular Dystrophy: Modern Approaches in Patient Management. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2023;20(5):427–453. (In Russ) https://doi.org/10.15690/pf.V20i5.2615 ]

6. Татаринцева З.Г., Бабичева О.В., Барбухатти К.О. Острый коронарный синдром с подъемом сегмента ST у ребенка с мышечной дистрофией Дюшенна: клинический случай. Российский кардиологический журнал. 2024;29(10S):5763. https://doi.org/10.15829/1560-4071-2024-5763 [Tatarintseva Z.G., Babicheva O.V., Barbuhatti K.O. ST-segment elevation acute coronary syndrome in a child with Duchenne muscular dystrophy: a case report. Russian Journal of Cardiology. 2024;29(10S):5763. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5763 ]

7. McDonald C.M., Muntoni F., Penematsa V. et al.; Study 019 investigators. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J Comp Eff Res. 2022;11(3):139-155. https://doi.org/10.2217/cer-2021-0196

8. US Food and Drug Administration. FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy. https://www. fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy (2024)

9. Chang M., Cai Y., Gao Z. et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270:3733– 3749. https://doi.org/10.1007/s00415-023-11796-x

10. Muntoni F., Tejura B., Spinty S. et al. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet. Clin Pharmacol Drug Dev. 2019;8(7):922-933. https://doi.org/10.1002/cpdd.642


Review

For citations:


Mayanskaya S.D., Bulashova O.V., Mukhitova E.I., Khazova E.V. Heart failure in Duchenne's progressive muscular dystrophy (case report). Eurasian heart journal. 2026;(1):64-69. (In Russ.) https://doi.org/10.38109/2225-1685-2026-1-64-69

Views: 261

JATS XML

ISSN 2225-1685 (Print)
ISSN 2305-0748 (Online)